Patents by Inventor Gijs HARDENBERG

Gijs HARDENBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
    Patent number: 11517618
    Abstract: Methods of inducing an immune response against human immunodeficiency virus (HIV) are described. In particular, methods of inducing an immune response against HIV by co-locally administering an immunogenically effective amount of an isolated HIV envelope (Env) polypeptide and an immunogenically effective amount of an adenovirus vector encoding an HIV antigen, e.g., Env antigen are described. The isolated HIV Env polypeptide and adenovirus vector can be administered in a single composition or in separate compositions, in which the composition or compositions do not contain an adjuvant.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 6, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Frank Wegmann, Gijs Hardenberg, Roland Christian Zahn
  • HIV vaccine regimens
    Publication number: 20220118081
    Abstract: Methods are described for generating an improved effective immune response against an HIV antigen in humans. The methods comprise administration of a first composition comprising an MVA vector followed by administration of second composition comprising a human adenovirus vector. The methods can be used for the treatment of HIV.
    Type: Application
    Filed: October 19, 2021
    Publication date: April 21, 2022
    Inventors: Frank WEGMANN, Maria Grazia PAU, Gijs HARDENBERG, Sietske Karla ROSENDAHL HUBER, Sanne KROOS
  • METHOD OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS BY CO-LOCALIZED ADMINISTRATION OF VACCINE COMPONENTS
    Publication number: 20200093917
    Abstract: Methods of inducing an immune response against human immunodeficiency virus (HIV) are described. In particular, methods of inducing an immune response against HIV by co-locally administering an immunogenically effective amount of an isolated HIV envelope (Env) polypeptide and an immunogenically effective amount of an adenovirus vector encoding an HIV antigen, e.g., Env antigen are described. The isolated HIV Env polypeptide and adenovirus vector can be administered in a single composition or in separate compositions, in which the composition or compositions do not contain an adjuvant.
    Type: Application
    Filed: September 23, 2019
    Publication date: March 26, 2020
    Inventors: Frank WEGMANN, Gijs HARDENBERG, Roland Christian ZAHN